-
1
-
-
84942860119
-
How i treat patients with bone metastases
-
Lipton A. How I treat patients with bone metastases. Oncology Times 2013; 35:32-34.
-
(2013)
Oncology Times
, vol.35
, pp. 32-34
-
-
Lipton, A.1
-
2
-
-
84867582660
-
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
-
Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-3092.
-
(2012)
Eur J Cancer
, vol.48
, pp. 3082-3092
-
-
Lipton, A.1
Fizazi, K.2
Stopeck, A.T.3
-
3
-
-
84875074661
-
Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice
-
So A, Chin J, Fleshner N, Saad F. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J 2012; 6:465-470.
-
(2012)
Can Urol Assoc J
, vol.6
, pp. 465-470
-
-
So, A.1
Chin, J.2
Fleshner, N.3
Saad, F.4
-
4
-
-
84890603325
-
Bone-targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigms
-
El-Amm J, Freeman A, Patel N, Aragon-Ching JB. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer 2013; 2013:210686.
-
(2013)
Prostate Cancer
, vol.2013
, pp. 210686
-
-
El-Amm, J.1
Freeman, A.2
Patel, N.3
Aragon-Ching, J.B.4
-
5
-
-
84872507131
-
Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
-
Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013; 5:1-14.
-
(2013)
Cancer Manag Res
, vol.5
, pp. 1-14
-
-
Harrison, M.R.1
Wong, T.Z.2
Armstrong, A.J.3
George, D.J.4
-
6
-
-
84884777163
-
Radium-223 (alpharadin) a novel targeted alpha-emitter for bone-metastatic castrate-resistant prostate cancer
-
Sartor O. Radium-223 (alpharadin) a novel targeted alpha-emitter for bone-metastatic castrate-resistant prostate cancer. PCRI Insights 2012; 9-15.
-
(2012)
PCRI Insights
, pp. 9-15
-
-
Sartor, O.1
-
7
-
-
5444242637
-
Bisphosphonates: Preclinical review
-
Green JR. Bisphosphonates: preclinical review. Oncologist 2004; 9 (Suppl 4): 3-13.
-
(2004)
Oncologist
, vol.9
, pp. 3-13
-
-
Green, J.R.1
-
8
-
-
84871918834
-
New and emerging therapies for bone metastases in genitourinary cancers
-
Saylor PJ, Armstrong AJ, Fizazi K, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013; 63:309-320.
-
(2013)
Eur Urol
, vol.63
, pp. 309-320
-
-
Saylor, P.J.1
Armstrong, A.J.2
Fizazi, K.3
-
9
-
-
20644447798
-
First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases
-
Sten Nilsson RHL, Fossa Sophie D, et al. First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-4459.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4451-4459
-
-
Nilsson RHL, S.1
Fossa Sophie, D.2
-
10
-
-
84873864130
-
Bone-tarageting radiopharmaceuticals including radium-223
-
Darren Brady CCP, O'Sullivan Joe M. Bone-tarageting radiopharmaceuticals including radium-223. Cancer J 2013; 19:71-78.
-
(2013)
Cancer J
, vol.19
, pp. 71-78
-
-
Brady CCP, D.1
O'Sullivan Joe, M.2
-
11
-
-
84881630281
-
Phase i pharmaco-kinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichlor-ide in men with castration-resistant metastatic prostate cancer
-
Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, et al. Phase I pharmaco-kinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichlor-ide in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40:1384-1393.
-
(2013)
Eur J Nucl Med Mol Imaging
, vol.40
, pp. 1384-1393
-
-
Carrasquillo, J.A.1
O'Donoghue, J.A.2
Pandit-Taskar, N.3
-
12
-
-
2942518111
-
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
-
Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 879-882
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
13
-
-
0037009822
-
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
-
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1458-1468
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
14
-
-
78149356666
-
Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer
-
Saad F, Eastham J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 2010; 76:1175-1181.
-
(2010)
Urology
, vol.76
, pp. 1175-1181
-
-
Saad, F.1
Eastham, J.2
-
15
-
-
84901944163
-
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (alliance)
-
Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 2014; 32:1143-1150.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1143-1150
-
-
Smith, M.R.1
Halabi, S.2
Ryan, C.J.3
-
16
-
-
69049105440
-
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
-
Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
-
(2009)
N Engl J Med
, vol.361
, pp. 745-755
-
-
Smith, M.R.1
Egerdie, B.2
Hernandez Toriz, N.3
-
17
-
-
84855516339
-
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial
-
Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46.
-
(2012)
Lancet
, vol.379
, pp. 39-46
-
-
Smith, M.R.1
Saad, F.2
Coleman, R.3
-
18
-
-
79551568488
-
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study
-
Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
-
(2010)
J Clin Oncol
, vol.28
, pp. 5132-5139
-
-
Stopeck, A.T.1
Lipton, A.2
Body, J.J.3
-
19
-
-
79952360832
-
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study
-
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
-
(2011)
Lancet
, vol.377
, pp. 813-822
-
-
Fizazi, K.1
Carducci, M.2
Smith, M.3
-
20
-
-
79952761418
-
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
-
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125-1132.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1125-1132
-
-
Henry, D.H.1
Costa, L.2
Goldwasser, F.3
-
21
-
-
84858706749
-
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
-
Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012; 48:678-686.
-
(2012)
Eur J Cancer
, vol.48
, pp. 678-686
-
-
Nilsson, S.1
Strang, P.2
Aksnes, A.K.3
-
22
-
-
84874543674
-
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone me-tastases
-
Nilsson S, Franzen L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone me-tastases. Clin Genitourin Cancer 2013; 11:20-26.
-
(2013)
Clin Genitourin Cancer
, vol.11
, pp. 20-26
-
-
Nilsson, S.1
Franzen, L.2
Parker, C.3
-
23
-
-
84874543674
-
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases
-
Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase ii study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013; 11:20-26.
-
(2013)
Clin Genitourin Cancer
, vol.11
, pp. 20-26
-
-
Nilsson, S.1
Franzén, L.2
Parker, C.3
-
24
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213-223.
-
(2013)
N Engl J Med
, vol.369
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
26
-
-
5444243800
-
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
-
Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9 (Suppl 4):28-37.
-
(2004)
Oncologist
, vol.9
, pp. 28-37
-
-
Conte, P.1
Guarneri, V.2
-
27
-
-
84891437622
-
-
Zoledronic Acid-Cancer Care Ontario
-
Zoledronic Acid-Cancer Care Ontario https://www.cancercare.on.ca/2013. Drug Monograph.
-
(2013)
Drug Monograph
-
-
-
28
-
-
84860467736
-
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
-
Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23:1341-1347.
-
(2012)
Ann Oncol
, vol.23
, pp. 1341-1347
-
-
Saad, F.1
Brown, J.E.2
Van Poznak, C.3
-
29
-
-
84860467736
-
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
-
Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23:1341-1347.
-
(2012)
Ann Oncol
, vol.23
, pp. 1341-1347
-
-
Saad, F.1
Brown, J.E.2
Van Poznak, C.3
-
30
-
-
84888188544
-
Robot assistedradical prostatectomy:how i do it. Part I: Patient preparation and positioning
-
Valdivieso RF, Hueber PA, Zorn KC. Robot assistedradical prostatectomy:how I do it. Part I: Patient preparation and positioning. Can J Urol 2013; 20:6957-6961.
-
(2013)
Can J Urol
, vol.20
, pp. 6957-6961
-
-
Valdivieso, R.F.1
Hueber, P.A.2
Zorn, K.C.3
-
31
-
-
33544469496
-
The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. II. Products of suppressor genes Rband PTEN, CDKI, Fas. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc
-
Knillova J, Kolar Z, Hlobilkova A. The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. II. Products of suppressor genes Rband PTEN, CDKI, Fas. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc. Czechoslovakia 2003;147:11-17.
-
(2003)
Czechoslovakia
, vol.147
, pp. 11-17
-
-
Knillova, J.1
Kolar, Z.2
Hlobilkova, A.3
-
32
-
-
34347244905
-
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study
-
Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8:587-594.
-
(2007)
Lancet Oncol
, vol.8
, pp. 587-594
-
-
Nilsson, S.1
Franzen, L.2
Parker, C.3
-
33
-
-
20644447798
-
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases
-
Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-4459.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4451-4459
-
-
Nilsson, S.1
Larsen, R.H.2
Fossa, S.D.3
-
34
-
-
84871926771
-
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (ra 223) in patients with bone metastases and castration-resistant prostate cancer
-
Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013; 63:189-197.
-
(2013)
Eur Urol
, vol.63
, pp. 189-197
-
-
Parker, C.C.1
Pascoe, S.2
Chodacki, A.3
-
35
-
-
30944461586
-
PTEN and GSK3beta: Key regulators of progression to androgen-independent prostate cancer
-
Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Onco-gene 2006; 25:329-337.
-
(2006)
Onco-gene
, vol.25
, pp. 329-337
-
-
Mulholland, D.J.1
Dedhar, S.2
Wu, H.3
Nelson, C.C.4
|